SomaLogic Announces Analyst and Investor Meeting on February 4, 2022

BOULDER, Colo., Jan. 07, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, will host a virtual Analyst and Investor Meeting on Friday, February 4, 2022, beginning at 10:00 a.m. Eastern Time. The virtual event will feature presentations from company leaders outlining SomaLogic’s unique positioning in proteomics, financial profile, and plans for continued business evolution and growth as the company furthers its scientific and commercial progress. The event will also feature a live panel with key opinion leaders and a Q&A session following speaker presentations.

SomaLogic management will also be presenting at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 8:15 a.m. Eastern Time.

A live and archived webcast of both events will be on the “Investors” section of the company’s website at https://investors.somalogic.com.

About SomaLogicSomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful, and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s personalized measurement of important changes in an individual’s proteins over time. For more information, visit www.somalogic.com and follow @somalogic on Twitter.

The SomaScan Platform is for Research Use Only (RUO) and has not been cleared or approved by the U.S. Food and Drug Administration for diagnostic or patient management purposes.

SomaLogic ContactEmilia Costales720-798-5054[email protected]

Investor ContactMarissa BychGilmartin Group LLC[email protected]

Source: SomaLogic, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Cogent Communications Holdings Securities Fraud Class Action Result of Undisclosed Demand and Backlog Issues and approximately 29% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick
• PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti,
• Simply Good Foods Company Securities Fraud Class Action Result of Undisclosed Acquisition Failures and Over 27% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC